MRNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Moderna Inc (MRNA) is not a good buy for a beginner, long-term investor at this time. The company's financial performance is deteriorating, analysts have lowered price targets significantly, and the stock faces negative sentiment due to the FDA's rejection of its flu vaccine application. Additionally, technical indicators and trading signals do not suggest a strong entry point. Given the investor's preference for long-term growth, it is better to wait for more clarity on the company's growth prospects and financial stability.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 32.239, showing no clear signal. The stock is trading near its support level of 37.888, with resistance at 41.678. Converging moving averages suggest indecision in the market.
NULL identified. The company has no recent positive developments, and the upcoming earnings report is expected to show significant losses.
has negatively impacted the stock. Analysts have lowered price targets, and hedge funds are selling heavily. Financial performance is deteriorating, with significant revenue and net income declines.
In Q3 2025, revenue dropped by 45.44% YoY to $1.016 billion. Net income fell by 1638.46% YoY to -$200 million, and EPS declined by 1800% YoY to -$0.51. Gross margin increased slightly to 86.22%, up 2.78% YoY, but this does not offset the overall poor financial performance.
Analysts are bearish on the stock. BofA and Leerink have lowered price targets to $24 and $12, respectively, with underperform ratings. UBS downgraded the stock to Neutral with a price target of $34. There is a lack of confidence in the company's ability to achieve meaningful revenue growth or profitability in the near term.
